Acetylsalicylic acid use is associated with improved survival in bacteremic pneumococcal pneumonia: A long-term nationwide study.

Kristján G Rögnvaldsson Agnar BjarnasonKarl KristinssonHörður T BragasonHelga ErlendsdóttirGuðmundur ÞorgeirssonMagnus Gottfredsson

Published in: Journal of internal medicine (2022)

Use of ASA upon admission for bacteremic pneumococcal pneumonia is associated with significantly reduced mortality for up to 1 year after diagnosis. ASA therapy in patients with pneumonia and other infectious syndromes warrants further study.

Keyphrases

emergency department
urinary tract infection
community acquired pneumonia
respiratory failure
cardiovascular events
risk factors
stem cells
coronary artery disease
free survival
mechanical ventilation